New RSV vaccine for older adults can result in individual and societal cost savings, benefits
September 05, 2024
September 05, 2024
ANN ARBOR, Michigan, Sept. 5 -- The University of Michigan issued the following news:
Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.
Study: Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus (DOI: 10.1016/j.vaccine.2024.126294)
The study conducted by researchers at . . .
Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.
Study: Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus (DOI: 10.1016/j.vaccine.2024.126294)
The study conducted by researchers at . . .